Photo Twan Lammers


Twan Lammers studied Pharmacy at the University of Utrecht. He obtained a DSc degree in Radiation Oncology from Heidelberg University in 2008, and a PhD degree in Pharmaceutics from Utrecht University in 2009. From 2007 until 2010, he worked as a Postdoctoral Fellow at the Department of Pharmaceutics at Utrecht University. Since 2009, he has been appointed as a Group Leader at the Department of Experimental Molecular Imaging at the University Clinic and the Helmholtz Center for Biomedical Engineering at RWTH Aachen University. Since 2012, he has also been appointed as a part-time Assistant Professor at the Department of Targeted Therapeutics at the University of Twente. He is an Editorial Board Member of the American Journal of Nuclear Medicine and Molecular Imaging, the Journal of Controlled Release, and Theranostics. His primary research interests include drug targeting to tumors, image-guided drug delivery and tumor-targeted combination therapies.


1.Lammers T, Kühnlein R, Kissel M, Subr V, Etrych T, Pola R, Pechar M, Ulbrich K, Storm G, Huber P, Peschke P. Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. J Control Release 110: 103-118 (2005) (IF=6.50)

2.Kiessling F, Heilmann M, Lammers T, Ulbrich K, Subr V, Peschke P, Wängler B, Mier W, Schrenk H, Bock M, Schad L, Semmler W. Synthesis and characterization of HE-24.8: a polymeric contrast agent for MR Angiography. Bioconjug Chem 17: 42-51 (2006) (IF=4.93)

3.Lammers T, Peschke P, Kühnlein R, Subr V, Ulbrich K, Huber P, Hennink W, Storm G. Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems. Neoplasia 8: 788-795 (2006) (IF=5.95)

4.Lammers T, Subr V, Ulbrich K, Kiessling F, Huber P, Peschke P. HPMA copolymers for cancer diagnosis and therapy. Eur J Clin Invest 36: S53 (2006) (IF=3.02)

5.Lammers T, Ehemann V, Debus J, Peschke P, Huber P, Lavi S. Role of PP2Cα in cell growth, in radio- and chemosensitivity, and in tumorigenicity. Mol Cancer 6: 65 (2007) (IF=3.99)

6.Lammers T, Lavi S. Role of type 2C protein phosphatases in growth regulation and cellular stress signalling. Crit Rev Biochem Mol Biol 42: 437-461 (2007) (IF=8.93)

7.Lammers T, Peschke P, Kühnlein R, Subr V, Ulbrich K, Debus J, Huber P, Hennink W, Storm G. Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. J Control Release 117: 333-341 (2007) (IF=6.50)

8.Zhang C, Jugold M, Wönne E, Lammers T, Morgenstern B, Müller M, Zentgraf H, Bock M, Eisenhut M, Semmler W, Kiessling F. Specific targeting of tumor angiogenesis by RGD-conjugated USPIO using a clinical 1.5 T MR-scanner. Cancer Res 67: 1555-1562 (2007) (IF=7.86)

9.Lammers T, Hennink W, Storm G. Tumor-targeted nanomedicines: principles and practice. Br J Cancer 99: 392-397 (2008) (IF=5.04)

10.Lammers T, Subr V, Peschke P, Kühnlein R, Hennink W, Ulbrich K, Kiessling F, Heilmann M, Debus J, Huber P, Storm G. Image-guided and passively tumor-targeted polymeric nanomedicines for radiochemotherapy. Br J Cancer 99: 900-910 (2008) (IF=5.04)

11.Lammers T, Subr V, Ulbrich K, Peschke P, Kiessling F, Huber P, Hennink W, Storm G. Carrier-based radiochemotherapy. J Control Release 132: e70 (2008) (IF=6.50)

12.Lammers T, Subr V, Ulbrich K, Peschke P, Huber P, Hennink W, Storm G. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 30: 3466-3475 (2009) (IF=7.40)

13.Talelli M, Rijcken C, Lammers T, Storm G, van Nostrum C, Hennink W. SPION nanoparticles encapsulated in biodegradable thermosensitive polymeric micelles: toward a targeted nanomedicine suitable for image-guided drug delivery. Langmuir 25: 2060-2067 (2009) (IF=4.17)

14.Crielaard B, Yousefi A, Schillemans J, Lammers T, Storm G. Interaction of liposomes with proteins measured by surface plasmon resonance correlates with their in vivo circulation time. J Control Release 148: e31-32 (2010) (IF=6.50)

15.Kunjachan S, Jose S, Lammers T. Understanding the mechanism of ionic gelation for synthesis of chitosan nanoparticles using qualitative techniques. Asian J Pharm 4: 148-153 (2010)

16.Lammers T. Nanoformuleringen voor radiochemotherapie. Pharm Weekbl 145: 24-26 (2010)

17.Lammers T. Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. Adv Drug Deliv Rev 62: 203-231 (2010) (IF=11.50)

18.Lammers T, Dawson W, Storm G, MediTrans: An Integrated Project focusing on targeted nanomedicines sponsored by the European Commission’s Framework Programme 6. Drug Discovery 7: 63-67 (2010)

19.Lammers T, Kiessling F, Hennink W, Storm G. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharmaceut 7: 1899-1912 (2010) (IF=4.78)

20.Lammers T, Storm G, Kiessling F. Nanomedicine formulations for combination therapies. Nano Reviews 1: 5705 (2010)

21.Lammers T, Subr V, Ulbrich K, Hennink W, Storm G, Kiessling F. Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy. Nano Today 5: 197-212 (2010) (IF=15.36)

22.Lammers T, Subr V, Ulbrich K, Peschke P, Huber P, Kiessling F, Hennink W, Storm G. HPMA-based polymer therapeutics for improving the efficacy of surgery, of radiotherapy and of chemotherapy combinations. Nanomedicine 5: 1501-1523 (2010) (IF=5.06)

23.Lammers T, Subr V, Ulbrich K, Peschke P, Huber P, Hennink W, Storm G, Kiessling F. Long-circulating and passively tumor-targeted polymer-drug conjugates improve the efficacy and reduce the toxicity of radiochemotherapy. Adv Eng Mater 12: B413-421 (2010) (IF=1.19)

24.Lammers T, Ulbrich K. HPMA copolymers: 30 years of advances. Adv Drug Deliv Rev 62: 119-121 (2010) (IF=11.50)

25.Talelli M, Iman M, Varkouhi A, Rijcken C, Schiffelers R, Etrych T, Ulbrich K, van Nostrum C, Lammers T, Storm G, Hennink W. Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin. Biomaterials 31: 7797-804 (2010) (IF=7.40)

26.Varkouhi AK, Verheul RJ, Schiffelers R, Lammers T, Storm G, Hennink W. Gene Silencing Activity of siRNA Polyplexes Based on Thiolated N,N,N-Trimethylated Chitosan. Bioconjug Chem 21: 2339-2346 (2010) (IF=4.93)

27.Varkouhi A, Schiffelers R, Van Steenbergen M, Lammers T, Hennink W, Storm G. Photochemical internalization (PCI)-mediated enhancement of gene silencing efficiency of polymethacrylates and N,N,N-trimethylated chitosan (TMC) based siRNA polyplexes. J Control Release 148: e98-99 (2010) (IF=6.50)

28.Crielaard B, Lammers T, Morgan M, Chaabane L, Carboni S, Greco B, Kraneveld A, Storm G. Macrophages and liposomes in inflammatory disease: friends or foes? Int J Pharm 416:499-506 (2011) (IF=3.35)

29.Crielaard B, Van der Wal S, Le H, Lammers T, Hennink W, Schiffelers R, Storm G, Fens M. A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy. Int J Nanomed 6: 2697-2703 (2011) (IF=3.13)

30.Crielaard B, Yousefi A, Schillemans J, Vermehren C, Buyens K, Braekmans K, Lammers T, Storm G. An in vitro assay based on surface plasmon resonance to predict the in vivo circulation kinetics of liposomes. J Control Release 156: 307-314 (2011) (IF=6.50)

31.Gremse F, Grouls C, Palmowski M, Lammers T, de Vries A, Grüll H, Das M, Mühlenbruch G, Akhtar S, Schober A, Kiessling F. Virtual Elastic Sphere Processing Enables Reproducible Quantification of Vessel Stenosis in CT and MR Angiographies. Radiology 260: 709-717 (2011) (IF=5.73)

32.Huis in ’t Veld R, Storm G, Hennink W, Kiessling F, Lammers T. Macromolecular nanotheranostics for multimodal anticancer therapy. Nanoscale 3: 4022-4034 (2011) (IF=5.91)

33.Jayapaul J, Hodenius M, Arns S, Lederle W, Lammers T, Comba P, Kiessling F, Gätjens J. FMN-coated fluorescent iron oxide nanoparticles for targeting and labeling metabolically active cancer and endothelial cells via the riboflavin carrier protein. Biomaterials 32: 5863-5871 (2011) (IF=7.40)

34.Kostka L, Cestmir K, Subr V, Spirkova M, Addadi Y, Neeman M, Lammers T, Ulbrich K. Removable nanocoatings for siRNA polyplexes. Bioconjug Chem 22: 169-179 (2011) (IF=4.93)

35.Lammers T, Aime S, Hennink W, Storm G, Kiessling F. Theranostic Nanomedicine. Acc Chem Res 44: 1029-1038 (2011) (IF=21.64)

36.Liehn E, Tuchscheerer N, Kanzler I, Drechsler M, Fraehmos L, Schuh A, Koenen R, Zandler S, Soehnlein O, Hristov M, Grigorescu G, Urs A, Leabu M, Bucur I, Merx M, Zernecke A. Ehling J, Gremse F, Lammers T, Kiessling F, Bernhagen J, Schober A, Weber C. Double-edged role of the CXCL12-CXCR4 axis in experimental myocardial infarction. J Am Coll Cardiol 58: 2415-2423 (2011) (IF=14.16)

37.Liu Z, Lammers T, Ehling J, Fokong S, Bornemann J, Kiessling F, Gätjens J. Iron Oxide Nanoparticle-Containing Microbubble Composites as Contrast Agents for MR and Ultrasound Dual-Modality Imaging. Biomaterials 32: 6155-6163 (2011) (IF=7.40)

38.Talelli M, Morita K, Rijcken C, Aben R, Lammers T, Scheeren H, Van Nostrum C, Storm G, Hennink W. Synthesis and characterization of biodegradable and thermosensitive polymeric micelles with covalently bound doxorubicin-glucuronide prodrug via click chemistry. Bioconj Chem 22: 2519-2530 (2011) (IF=4.93)

39.Talelli M, Rijcken C, Oliveria S, Van Meel R, Van Bergen en Henegouwen P, Lammers T, Van Nostrum C, Storm G, Hennink W. Nanobody-shell functionalized thermosensitive polymeric micelles for active targeting. J Control Release 153: 93-102 (2011) (IF=6.50)

40.Varkouhi A, Foillard S, Lammers T, Schiffelers R, Doris E, Hennink W, Storm G. Nucleic Acid Delivery with Functionalized Carbon Nanotubes. Int J Pharm 416:419-25 (2011) (IF=3.35)

41.Varkouhi A, Lammers T, Schiffelers R, Van Steenbergen M, Hennink W, Storm G. Gene silencing efficiency of siRNA polyplexes based on biodegradable polymers. Eur J Pharm Biopharm 77: 450-457 (2011) (IF=4.27)

42.Wiessler M, Hennrich U, Pipkorn R, Waldeck W, Cao L, Peter J, Ehemann V, Semmler W, Lammers T, Braun K. Theranostic cRGD-BioShuttle Constructs Containing Temozolomide- and Cy7 For NIR-Imaging and Therapy.
Theranostics 1: 381-394 (2011) (IF=5.09)

43.Braun K, Beining M, Wiessler M, Lammers T, Pipkorn R, Hennrich U, Nokihara K, Semmler W, Debus J, Waldeck W. BioShuttle Mobility in Living Cells Studied with High-Resolution FCS & CLSM Methodologies. Int J Med Sci 9: 339-352 (2012) (IF=2.24)

44.Cittadino E, Ferraretto M, Torres E, Maiocchi A, Crielaard B, Lammers T, Storm G, Aime S, Terreno E, MRI evaluation of the antitumor activity of paramagnetic liposomes loaded with prednisolone phosphate. Eur J Pharm Sci 45: 436-441 (2012) (IF=3.06)

45.Crielaard B, Rijcken C, Quan L, Van der Wal S, Altintas I, Van der Pot M, Kruijtzer J, Liskamp R, Schiffelers R, Van Nostrum C, Hennink W, Wang D, Lammers T*, Storm G*. Glucocorticoid-loaded core-crosslinked polymeric micelles with tailorable release kinetics for targeted rheumatoid arthritis therapy. Angew Chem Int Ed 51: 7254-7258 (2012) (IF=12.73)

46.Crielaard B, Schiffelers R, Lammers T, Storm G. Drug targeting in inflammatory disease: one for all, all for one. J Control Release 161: 225-234 (2012) (IF=6.50)

47.Crielaard B, Van der Wal S, Le H, Bode A, Lammers T, Hennink W, Schiffelers R, Storm G, Fens M. Liposomes as carriers for colchicine-derived prodrugs: vascular disrupting nanomedicines with tailorable drug release kinetics. Eur J Pharm Sci 45: 429-435 (2012) (IF=3.21)

48.Fokong S, Theek B, Wu Z, Koczera P, Appold L, Jorge S, Resch-Genger U, van Zandvoort M, Storm G, Kiessling F, Lammers T. Image-guided, targeted and triggered drug delivery to tumors using polymer-based microbubbles. J Control Release 163: 75-81 (2012) (IF=6.50)

49.Hodenius M, Wuerth C, Jayapaul J, Wong J, Lammers T, Gaetjens J, Arns S, Mertens M, Slabu I, Ivanova G, De Cuyper M, Resch-genger U, Kiessling F. Fluorescent magnetoliposomes as a platform technology for functional and molecular MR and optical imaging. Contrast Media Mol Imaging 7: 59-67 (2012) (IF=3.33)

50.Jensen L, Griger J, Maeye B, Varkouhi A, Raemdonck K, Schiffelers R, Lammers T, Storm G, de Smedt S, Sproat B, Nielsen H, Foged C. Comparison of polymeric siRNA nanocarriers in a murine LPS-activated macrophage cell line: Gene silencing, toxicity and off-target gene expression. Pharm Res 29: 669-682 (2012) (IF=4.09)

51.Kiessling F, Fokong S, Koczera P, Lederle W, Lammers T. Ultrasound microbubbles for molecular diagnosis, therapy and theranostics. J Nucl Med 53: 345-358 (2012) (IF=6.38)

52.Koczera P, Wu Z, Fokong S, Theek B, Appold L, Jorge S, Moeckel D, Liu Z, Curaj A, Storm G, van Zandvoort M, Kiessling F, Lammers T. Fluorescently labeled microbubbles for facilitating translational molecular ultrasound studies. Drug Deliv Transl Res 2: 56-64 (2012)

53.Kunjachan S, Blauz A, Moeckel D, Theek B, Kiessling F, Etrych T, Ulbrich K, van Bloois L, Storm G, Bartosz G, Rychlik B, Lammers T. Overcoming cellular multidrug resistance using classical nanomedicine formulations. Eur J Pharm Sci 45: 421-428 (2012) (IF=3.21)

54.Kunjachan S, Jayapaul J, Mertens M, Storm G, Kiessling F, Lammers T. Theranostic systems and strategies for monitoring nanomedicine-mediated drug targeting. Curr Pharm Biotech 13: 609-622 (2012) (IF=2.81)

55.Kunjachan S, Jose S, Cinu T, Joseph E, Kiessling F, Lammers T. Macrophage-mediated drug targeting in anti-microbial therapy. Fund Clin Pharm 26: 63-71 (2012) (IF=1.80)

56.Lammers T. Drug delivery research in Europe. J Control Release 161: 151 (2012) (IF=6.50)

57.Lammers T, Kiessling F, Hennink W, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 161: 175-187 (2012) (IF=6.50)

58.Lammers T. Nanomedicine on the move: from monotherapeutic regimens to combination therapies. Expert Rev Clin Pharmacol 5: 105-108 (2012)

59.Lammers T, Rizzo L, Storm G, Kiessling F. Personalized nanomedicine. Clin Cancer Res 18: 4889-4894 (2012) (IF: 7.34)

60.Leonard F, Ali H, Collnot E, Crielaard B, Lammers T, Storm G, Lehr C. Screening of budesonide nanoformulations for treatment of inflammatory bowel disease in an inflamed 3D cell-culture model. ALTEX 29: 275-285 (2012) (IF=4.43)

61.Te Boekhorst B, Jensen LB, Colombo S, Varkouhi A, Schiffelers R, Lammers T, Storm G, Nielsen H, Strijkers G, Foged C, Nicolay K. MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model. J Control Release 161: 772-780 (2012) (IF=6.50)

62.Varkouhi A, Mountrichas G, Schiffelers R, Lammers T, Storm G, Pispas S, Hennink W. Polyplexes based on cationic polymers with strong nucleic acid binding properties. Eur J Pharm Sci 45: 459-466 (2012) (IF=3.21)

63.Bartneck M, Ritz T, Keul H, Wambach M, Bornemann J, Gbureck U, Ehling J, Lammers T, Heymann F, Gassler N, Luedde T, Trautwein C, Groll J, Tacke F. Peptide-Functionalized Gold Nanorods Increase Liver Injury in Hepatitis. ACS Nano 23: 8767-8777 (2012) (IF=11.42)

64.Frese J, Hrdlicka L, Mertens M, Rongen L, Koch S, Schuster P, Gesché V, Lammers T, Mela P, Kiessling F, Jockenhoevel S. Non-invasive Imaging of Tissue-Engineered Vascular Endothelium with Iron Oxide Nanoparticles. Biomed Tech (Berl) 57: 1065-1067 (2012)

65.Frese J, Schuster P, Mertens M, Vogg A, Dahlems U, Rongen L, Koch S, Mela P, Melmer G, Barth S, Mottaghy F, Schmitz-Rode T, Lammers T, Jockenhoevel S, Kiessling F. Generation and imaging of patient customized implants. Biomed Tech (Berl) 57: 4388 (2012)

66.Jayapaul J, Arns S, Lederle W, Lammers T, Comba P, Gätjens J, Kiessling F. Riboflavin carrier protein-targeted fluorescent USPIO for the assessment of vascular metabolism in tumors. Biomaterials 33: 8822-8829 (2012) (IF=7.40)

67.Tiebosch I, Crielaard B, Bouts M, Zwartbol R, Salas-Perdomo A, Lammers T, Planas A, Storm G, Dijkhuizen R. Combined treatment with recombinant tissue plasminogen activator and dexamethasone phosphate-containing liposomes improves neurological outcome and restricts lesion progression after embolic stroke in rats. J Neurochem 123: 64-74 (2012) (IF=4.06)

68.Talelli M, Oliveria S, Rijcken C, Pieters E, Etrych T, Ulbrich K, Van Nostrum C, Storm G, Hennink W, Lammers T. Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy. Biomaterials 34: 1255-1260 (2013) (IF=7.40)

69.Fuge F, Weiler M, Gaetjens J, Lammers T, Kiessling F. Comparison and systematic optimization of synthetic protocols for DOTA-hydrazide generation. Tetrahedron Lett (in press) (IF: 2.68)

70.Kunjachan S, Gremse F, Theek B, Koczera P, Pola R, Pechar M, Etrych T, Ulbrich K, Storm G, Kiessling F, Lammers T. Non-invasive optical imaging of nanomedicine biodistribution. ACS Nano (in press) (IF=11.42)

71.Talelli M, Rijcken C, Hennink W, Lammers T. Polymeric micelles for cancer therapy: 3 C’s to enhance efficacy. Curr Opin Solid State Mater Sci (in press) (IF=4.23)

72.Ehling J, Bartneck M, Botnar R, Lammers T*, Tacke F*. Elastin-based molecular MRI of liver fibrosis. Hepatology (in press) (IF=11.67)